TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14621718

Group type: EXPERIMENTAL
Intervention: Four different immunosuppressive regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment groups
Number of subjects: 0
Study: 3902413

Group type: EXPERIMENTAL
Intervention: Topical ampicillin (1 g in each surgical wound)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Intravenous antibiotics (ampicillin 1 g X 3 and metronidazole 0.5 g X 3)
Number of subjects: 203
Study: 31881991

Group type: EXPERIMENTAL
Intervention: Pharmacist-led therapeutic carbohydrate restricted (Pharm-TCR) diet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Guideline-based treatment as usual (TAU)
Number of subjects: 200
Study: 28969887

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 10^8 colony forming unit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26291594

Group type: EXPERIMENTAL
Intervention: High-dose intracoronary N-acetylcysteine (100 mg/kg bolus, followed by 10 mg·kg⁻¹·h⁻¹ for 12 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dextrose solution (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose intracoronary N-acetylcysteine
Number of subjects: 100
Study: 24044373

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) training program over 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 22920158

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 351

Group type: COMPARATOR
Intervention: Multidisciplinary intervention
Number of subjects: 351
Study: 20719315

Group type: EXPERIMENTAL
Intervention: Torsion adapter
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rigid adapter
Number of subjects: 10
Study: 17376183

Group type: EXPERIMENTAL
Intervention: Antenatal glucocorticoid (betamethasone)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Antenatal glucocorticoid (long exposure)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 16597681

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients (n = 24)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Uric acid stone formers (UASF; n = 8)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normal volunteers (NV; n = 59)
Number of subjects: 91
Study: 12631373

Group type: EXPERIMENTAL
Intervention: Icodextrin 7.5% solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard glucose solutions
Number of subjects: 40
Study: 10759661

Group type: EXPERIMENTAL
Intervention: Trospium chloride (TCl, 20 mg twice daily)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 8838434

Group type: EXPERIMENTAL
Intervention: 40 mg caroverine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80 mg caroverine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 120 mg caroverine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1349494

Group type: EXPERIMENTAL
Intervention: Cetirizine (2 x 10 mg daily for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2416297

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (norepinephrine uptake inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimeldine hydrochloride (serotonin uptake inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clorgyline (selective monoamine oxidase type A inhibitor)
Number of subjects: 0
Study: 30941442

Group type: EXPERIMENTAL
Intervention: Perineal massage and pelvic floor muscle training (PFMT) with educational program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Prevention education program only
Number of subjects: 200
Study: 30571502

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 21162
Study: 27926472

Group type: EXPERIMENTAL
Intervention: Sweetened beverage intake >2 servings daily (6% of participants)
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Each 200 mL daily serving of sweetened beverages
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Total sweetened beverage intake
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: High consumers of sweetened beverages in type 2 diabetes
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: High consumers of sweetened beverages in LADA
Number of subjects: 1864
Study: 25721356

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Prednisone plus Low-Dose Cyclophosphamide
Number of subjects: 33

Group type: COMPARATOR
Intervention: Docetaxel plus Prednisone
Number of subjects: 33
Study: 22525957

Group type: EXPERIMENTAL
Intervention: Diagnostic Interview Schedule for Children (DISC)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Child and Adolescent Psychiatric Assessment (CAPA)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Development and Well-Being Assessment (DAWBA)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: DAWBA
Number of subjects: 646

Group type: COMPARATOR
Intervention: DISC and CAPA
Number of subjects: 646
Study: 19717485

Group type: EXPERIMENTAL
Intervention: In‐DTPA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tc‐SC
Number of subjects: 21
Study: 18301949

Group type: EXPERIMENTAL
Intervention: Total laparoscopic restorative proctocolectomy
Number of subjects: 35
Study: 16291160

Group type: EXPERIMENTAL
Intervention: Elective delivery at 36 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Await spontaneous labor
Number of subjects: 42
Study: 12183217

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10337292

Group type: EXPERIMENTAL
Intervention: Ketac-Fil
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Photac-Fil
Number of subjects: 34
Study: 9026175

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (transdermal estrogen patch)
Number of subjects: 41
Study: 1672137

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Psoralen + UVA (PUVA) therapy
Number of subjects: 7
Study: 6752871

Group type: EXPERIMENTAL
Intervention: Pirprofen (1200 mg, 400 mg t.i.d.)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg, 50 mg t.i.d.)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 31903802

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (10 µg/m3 increase in 1-month mean)
Number of subjects: 165675

Group type: EXPERIMENTAL
Intervention: Shorter-duration PM10 exposures
Number of subjects: 165675
Study: 31209792

Group type: EXPERIMENTAL
Intervention: TAS-102
Number of subjects: 84
Study: 28350181

Group type: EXPERIMENTAL
Intervention: Catheter oxygen group with Hb ≤ 70 g/L
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Catheter oxygen group with 71 g/L ≤ Hb ≤ 90 g/L
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ventilator-assisted breathing group with 71 g/L ≤ Hb ≤ 90 g/L
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ventilator-assisted breathing group with Hb ≥ 91 g/L
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison of 71 g/L ≤ Hb ≤ 90 g/L subgroups
Number of subjects: 59
Study: 26228328

Group type: EXPERIMENTAL
Intervention: Semi-continuous technique for mitral valve replacement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interrupted suture technique for mitral valve replacement
Number of subjects: 100
Study: 23132045

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 10
Study: 21684428

Group type: EXPERIMENTAL
Intervention: Pandemic H1N1 live attenuated influenza vaccine (LAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAI assay
Number of subjects: 0
Study: 18443134

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil; Omegaven 10%; 0.15 - 0.2 g/kg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Soybean oil (Lipovenos 20%)
Number of subjects: 40
Study: 17194229

Group type: EXPERIMENTAL
Intervention: Combined uphill-downhill training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Downhill training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Horizontal training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 12544374

Group type: EXPERIMENTAL
Intervention: Intranasal AVP (2 x 20 IU) for 10 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11043125

Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 370

Group type: COMPARATOR
Intervention: Both operative and non-operative treatment
Number of subjects: 370

Group type: COMPARATOR
Intervention: Retrospective studies (both operative and conservative therapy)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 370
Study: 12056098

Group type: EXPERIMENTAL
Intervention: Dexrazoxane at 500 mg/m2 commencing at the seventh cycle of treatment
Number of subjects: 0
Study: 1529875

Group type: EXPERIMENTAL
Intervention: Pimobendan 5 mg daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 3903782

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31144762

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29297943

Group type: EXPERIMENTAL
Intervention: Wrapping in sandwiched sheets (two prewarmed sheets with a layer of newspaper)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (two prewarmed sheets without a layer of newspaper)
Number of subjects: 100
Study: 27423044

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roflumilast 0.375 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roflumilast N-oxide
Number of subjects: 0
Study: 25669214

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia (STD)
Number of subjects: 80
Study: 23983460

Group type: EXPERIMENTAL
Intervention: 16-week exercise intervention
Number of subjects: 378

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 378
Study: 21906396

Group type: EXPERIMENTAL
Intervention: Point of Care Technologies (POCT)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard laboratory service
Number of subjects: 239
Study: 19241855

Group type: EXPERIMENTAL
Intervention: Surgery for tumor combined with lymph dissection D2 and cytoreduction (R1 and R2)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Surgery for tumor combined with splenectomy
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Spleen re-plantation into the round ligament of the liver
Number of subjects: 587

Group type: COMPARATOR
Intervention: Controls (standard, palliative and diagnostic operations)
Number of subjects: 587
Study: 16314076

Group type: EXPERIMENTAL
Intervention: Active 10.0001‐Hz rTMS to the left temporoparietal cortex
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study: 12683708

Group type: EXPERIMENTAL
Intervention: Low level energy laser therapy (LLLT) with Gallium Arsenide laser irradiation at 890 nm
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sham irradiation (control)
Number of subjects: 130
Study: 11531635

Group type: EXPERIMENTAL
Intervention: 800 mcg misoprostol per rectum
Number of subjects: 64
Study: 10181070

Group type: EXPERIMENTAL
Intervention: Zileuton plus usual asthma care
Number of subjects: 2947

Group type: COMPARATOR
Intervention: Usual asthma care alone
Number of subjects: 2947
Study: 7917928

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a (IFN-alpha) 6 MU every 48 h
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no IFN-alpha)
Number of subjects: 19
Study: 3254763

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (0‐54 ng min‐1 kg‐1) for 15 min per dose
Number of subjects: 8
Study: 31878820

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 31356558

Group type: EXPERIMENTAL
Intervention: Oral nano vitamin D (60,000 IU/d for 8 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral nano vitamin D
Number of subjects: 0
Study: 28198572

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block with 0.2 ml·kg‐1 of 0.375% ropivacaine per side
Number of subjects: 34

Group type: COMPARATOR
Intervention: Local anesthetic infiltration with 0.2 ml·kg‐1 of 0.75% ropivacaine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block
Number of subjects: 34

Group type: COMPARATOR
Intervention: Local anesthetic infiltration
Number of subjects: 34
Study: 26258177

Group type: EXPERIMENTAL
Intervention: Self-adhesive flowable composite resin (SAFC) - Fusio Liquid Dentin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nanohybrid composite (E&Ra/nanoC) - G-aenial with three-step etch-and-rinse adhesive system (Optibond FL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 23931889

Group type: EXPERIMENTAL
Intervention: HA330 hemoperfusion treatment (N=25)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard therapy (N=21)
Number of subjects: 46
Study: 21757141

Group type: EXPERIMENTAL
Intervention: Dan-Chi-Liu-Wei combination (DCLWC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 19281572

Group type: EXPERIMENTAL
Intervention: Percutaneous shunting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16881780

Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse (CSA)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Alcohol use (for men)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Drug use (for women)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (for women)
Number of subjects: 827
Study: 15572490

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 10 mg ephedrine followed by a continuous infusion for 60 minutes of 20 mg ephedrine
Number of subjects: 145

Group type: COMPARATOR
Intervention: No ephedrine (control group)
Number of subjects: 145
Study: 11357168

Group type: EXPERIMENTAL
Intervention: 30 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: 75 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: 150 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 9146603

Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Electroejaculation
Number of subjects: 11
Study: 7525422

Group type: EXPERIMENTAL
Intervention: Total peritoneal fluid TAP concentration > or = nmol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Free fluid volume > 20 ml or free fluid colour > grade 5 on the Leeds chart
Number of subjects: 22
Study: 30349139

Group type: EXPERIMENTAL
Intervention: Monosodium L-glutamate (MSG) 0.9 g/dose, thrice daily
Number of subjects: 159

Group type: COMPARATOR
Intervention: NaCl 0.26 g/dose, thrice daily (Control group)
Number of subjects: 159
Study: 29549464

Group type: EXPERIMENTAL
Intervention: Allopurinol 5 mg/kg/day for 4 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study: 27436681

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cook cervical ripening balloon
Number of subjects: 78
Study: 24417452

Group type: EXPERIMENTAL
Intervention: Intervention group using time aids
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 47
Study: 22472578

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 19809829

Group type: COMPARATOR
Intervention: Metronidazole (7 days)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: OHP (7 days)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: OHP (14 days)
Number of subjects: 450
Study: 18976959

Group type: EXPERIMENTAL
Intervention: Vasomotor symptoms reported at 3-month follow-up
Number of subjects: 3964

Group type: EXPERIMENTAL
Intervention: Joint symptoms reported at 3-month follow-up
Number of subjects: 3964
Study: 16463821

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 0
Study: 14725500

Group type: EXPERIMENTAL
Intervention: 2 minutes video of a dentist explaining what an injection will feel like and proposing hand raising as a signal mechanism
Number of subjects: 101

Group type: COMPARATOR
Intervention: 2 minutes video of Disneyland
Number of subjects: 101
Study: 11864504

Group type: EXPERIMENTAL
Intervention: Bivalent inactivated vaccine
Number of subjects: 657
Study: 7573627

Group type: EXPERIMENTAL
Intervention: Mailed pamphlet and letter
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 2053

Group type: EXPERIMENTAL
Intervention: Home visit outreach intervention
Number of subjects: 2053

Group type: COMPARATOR
Intervention: Usual method of informing at Medicaid intake (Control)
Number of subjects: 2053
Study: 1936009

Group type: EXPERIMENTAL
Intervention: 30 units of Anisoylated Plasminogen Streptokinase Activator Complex (APSAC, eminase) intravenously by a mobile intensive care unit (MICU)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prehospital period
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hospital stay
Number of subjects: 62
Study: 6124906

Group type: EXPERIMENTAL
Intervention: Fazadinium (1 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 40
Study: 31434774

Group type: EXPERIMENTAL
Intervention: Conventional methods plus VR videos
Number of subjects: 322

Group type: COMPARATOR
Intervention: Conventional patient education
Number of subjects: 322
Study: 29609570

Group type: COMPARATOR
Intervention: Control condition: PE teachers encouraged students to participate in PA during leisure time without providing persuasive messages.
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Intervention condition: PE teachers delivered persuasive messages targeting salient benefits and barriers associated with PA during the last 5 to 10 minutes of each PE lesson.
Number of subjects: 171
Study: 26475166

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 15 mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 15 mL with 1:200,000 epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine 15 mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of warm sensation thresholds on one dermatome at 24 hr
Number of subjects: 0
Study: 25017575

Group type: EXPERIMENTAL
Intervention: Mepivacaine 2% plus adrenaline with sodium bicarbonate 1.4%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline 0.9%
Number of subjects: 100
Study: 23018435

Group type: EXPERIMENTAL
Intervention: Raltegravir (intensified arm, n = 30)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control therapy (control arm, n = 14)
Number of subjects: 44
Study: 20386508

Group type: EXPERIMENTAL
Intervention: Exogenous arginine vasopressin infusion (AVP) at doses of 0.033 IU/min and 0.067 IU/min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Decrease in copeptin levels during AVP therapy
Number of subjects: 39
Study: 17084411

Group type: EXPERIMENTAL
Intervention: TRAM
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LTD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 16278257

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Number of subjects: 982

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982
Study: 12404707

Group type: EXPERIMENTAL
Intervention: 0.6 mg of scopolamine (SP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.2 mg of scopolamine (SP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12569761

Group type: EXPERIMENTAL
Intervention: Larger dose of ribavirin
Number of subjects: 155

Group type: COMPARATOR
Intervention: Routine therapeutic dose of ribavirin (Control)
Number of subjects: 155
Study: 7804972

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms three times per day and tamoxifen 10 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Historic cohort (untreated patients)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Octreotide-tamoxifen group
Number of subjects: 12
Study: 2230868

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (MA), 800 mg/d
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (MA), 160 mg/d
Number of subjects: 172
Study: 466964

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (10 fractions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Air (15 or 20 fractions)
Number of subjects: 24
Study: 30654454

Group type: EXPERIMENTAL
Intervention: High-convective volume postdilution hemodiafiltration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 15
Study: 30073605

Group type: EXPERIMENTAL
Intervention: Neurofeedback Training (NFT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (mock NFT)
Number of subjects: 20
Study: 27067670

Group type: EXPERIMENTAL
Intervention: Stair climbing intervention (signs and enhancement of stairwell aesthetics)
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Stair climbing intervention (after intervention)
Number of subjects: 1328
Study: 25117820

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0